Cargando…
Metronomic Treatment with Low-Dose Trofosfamide Leads to a Long-Term Remission in a Patient with Docetaxel-Refractory Advanced Metastatic Prostate Cancer
The treatment of metastatic prostate cancer patients refractory to androgen withdrawal and docetaxel therapy is currently discouraging and new therapeutic approaches are vastly needed. Here, we report a long-term remission over one year in a 68-year-old patient with metastatic docetaxel-refractory p...
Autores principales: | Greiner, Jochen, Küfer, Rainer, Reske, Sven N., Martin, Volker, Döhner, Hartmut, Ringhoffer, Mark |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2853857/ https://www.ncbi.nlm.nih.gov/pubmed/20396674 http://dx.doi.org/10.1155/2010/395720 |
Ejemplares similares
-
Feasibility and tolerability of trofosfamide and etoposide in progressive glioblastoma
por: Schmidt, Teresa, et al.
Publicado: (2023) -
Feasibility of metronomic chemotherapy with tegafur-uracil, cisplatin, and
dexamethasone for docetaxel-refractory prostate cancer
por: Kubota, Hiroki, et al.
Publicado: (2017) -
Maintenance Treatment with Trofosfamide in Patients with Primary Bone Ewing Sarcoma – Single Center Experience
por: Raciborska, Anna, et al.
Publicado: (2019) -
Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
por: James, Nicholas D., et al.
Publicado: (2022) -
Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate
por: Dickinson, P D, et al.
Publicado: (2012)